The startup produces medicinal drugs utilizing cell-free membrane protein preparation technology and non-canonical amino acid incorporation to create therapeutics that maintain structural and functional integrity. This approach enables the development of targeted candidates for physiologically significant membrane proteins, addressing the need for effective treatments in medical care.
Funding
Funding not disclosed
Founders
Product
Problem
Many promising drug targets, particularly membrane proteins like GPCRs, are difficult to express in high quantities and maintain in a stable, functional state using traditional methods. This poses a significant challenge for drug discovery, as these proteins are often crucial for cellular signaling and represent attractive targets for therapeutic intervention.
Solution
LiberoThera leverages its proprietary cell-free membrane protein preparation technology and non-canonical amino acid incorporation techniques to produce high-quality membrane proteins that retain their native structure and function. This platform enables the development of novel therapeutics targeting physiologically relevant membrane proteins, including GPCRs, which have been historically challenging to address. By overcoming the limitations of conventional methods, LiberoThera facilitates the discovery of innovative drug candidates for diseases with high unmet medical needs. The technology allows for the efficient production of lipid-detergent mixed proteomicelles containing correctly folded membrane proteins, closely mimicking the native environment. This approach accelerates drug discovery by enabling effective screening and characterization of drug candidates targeting these complex proteins.
Target Audience
LiberoThera's primary customers include pharmaceutical companies, biotech firms, and academic institutions engaged in drug discovery and development, particularly those focused on membrane protein targets.
Features
- Cell-free protein synthesis system optimized for membrane protein production
- Non-natural amino acid incorporation for enhanced protein stability and functionality
- Proprietary lipid-detergent mixed micelle technology to maintain native protein structure
- High-throughput screening capabilities for antibody and small molecule drug discovery
- Target identification and validation for GPCRs and other membrane proteins
- Generation of customized membrane protein antigens for drug screening
- Capability to produce GPCR antigen proteins in a functionally folded state for drug screening applications